trending Market Intelligence /marketintelligence/en/news-insights/trending/DQcCMP_ZtAtcQjXkJPfpFA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Intra-Cellular Therapies prices $295M common stock offering

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Intra-Cellular Therapies prices $295M common stock offering

Intra-Cellular Therapies Inc. priced its public offering of 10 million common shares at $29.50 per share.

The New York-based biopharmaceutical company also granted underwriters a 30-day option to buy up to an additional 1.5 million common shares.

Gross proceeds are expected to be $295 million.

The offer is expected to close Jan. 10.

J.P. Morgan Securities LLC, SVB Leerink LLC and Evercore Group LLC are acting as joint book-running managers for the offer, while Cantor Fitzgerald & Co. and Canaccord Genuity LLC are acting as co-lead managers. JMP Securities LLC is acting as co-manager for the offering.

Intra-Cellular Therapies develops treatments for neuropsychiatric and neurodegenerative disorders. In December 2019, the U.S. Food and Drug Administration approved its medicine Caplyta to treat adults with schizophrenia.